Skip to main content
Explore URMC

Ruth B. Schneider, M.D.

(Pronouns: she/her/hers)

Contact Information

Phone Numbers

Appointment: (585) 341-7500

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

  • Associate Professor - Department of Neurology , Movement Disorders (SMD)
  • Associate Professor - Center for Health and Technology - Joint

Patient Care Setting



Dr. Schneider graduated from Brown University in 2006 and received her MD from the University of Rochester School of Medicine and Dentistry in 2010. She completed her neurology residency in 2014 and a movement disorders fellowship in 2015, both at the University of Rochester. She joined the faculty in 2015 and specializes in the care of patients with movement disorders, including Parkinson's disease, Huntington's disease, and essential tremor. She is the Director of our Huntington's Disease Society of America Center of Excellence.



MD | University of Rochester School of Medicine/Dentistry

Post-doctoral Training & Residency

07/01/2014 - 06/30/2015
Fellowship in Movement Disorders at University of Rochester Medical Center

07/01/2011 - 06/30/2014
Residency in Neurology at University of Rochester Medical Center

06/16/2010 - 06/30/2011
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL expand_more

Clinical Trials

The Parkinson's Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

Lead Researcher: Ruth Schneider

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of the study is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

View Study Details


Journal Articles

Dorsey ER, Zafar M, Lettenberger SE, Pawlik ME, Kinel D, Frissen M, Schneider RB, Kieburtz K, Tanner CM, De Miranda BR, Goldman SM, Bloem BR. "Trichloroethylene: An Invisible Cause of Parkinson's Disease?" Journal of Parkinson's disease.. 2023 13(2):203-218.

Jensen-Roberts S, Myers TL, Auinger P, Cannon P, Rowbotham HM, Coker D, Chanoff E, Soto J, Pawlik M, Amodeo K, Sharma S, Valdovinos B, Wilson R, Sarkar A, McDermott MP, Alcalay RN, Biglan K, Kinel D, Tanner C, Winter-Evans R, Augustine EF, Holloway RG, Dorsey ER, Schneider RB. "A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease: Baseline Results." Neurology. Genetics.. 2022 Oct; 8(5):e200008. Epub 2022 Aug 11.

Liu Y, Zhang G, Tarolli CG, Hristov R, Jensen-Roberts S, Waddell EM, Myers TL, Pawlik ME, Soto JM, Wilson RM, Yang Y, Nordahl T, Lizarraga KJ, Adams JL, Schneider RB, Kieburtz K, Ellis T, Dorsey ER, Katabi D. "Monitoring gait at home with radio waves in Parkinson's disease: A marker of severity, progression, and medication response." Science translational medicine.. 2022 Sep 21; 14(663):eadc9669. Epub 2022 Sep 21.